Detalhe da pesquisa
1.
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Cell
; 171(6): 1284-1300.e21, 2017 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-29195073
2.
Stereotactic ablative radiation therapy in metastatic prostate cancer.
Curr Opin Oncol
; 36(3): 180-185, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38362949
3.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
J Urol
; 211(4): 526-532, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38421252
4.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
J Urol
; 211(4): 509-517, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38421253
5.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
J Urol
; 211(4): 518-525, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38421243
6.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Cancer
; 129(14): 2169-2178, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37060201
7.
Single-nucleus chromatin accessibility identifies a critical role for TWIST1 in idiopathic pulmonary fibrosis myofibroblast activity.
Eur Respir J
; 62(1)2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37142338
8.
Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
Prostate
; 82(5): 551-555, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35014708
9.
Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
Prostate
; 82(16): 1520-1528, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35923127
10.
Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Prostate
; 82 Suppl 1: S73-S85, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35657158
11.
What are survivorship care plans failing to tell men after prostate cancer treatment?
Prostate
; 81(7): 398-406, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33755233
12.
Twist1 is required for the development of UVB-induced squamous cell carcinoma.
Mol Carcinog
; 60(5): 342-353, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33713497
13.
Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.
World J Urol
; 39(2): 317-326, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31955223
14.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32487038
15.
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
BMC Cancer
; 19(1): 572, 2019 Jun 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31196032
16.
Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
BJU Int
; 123(2): 252-260, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29626845
17.
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
World J Urol
; 37(12): 2623-2629, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-30191396
18.
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?
Oncology (Williston Park)
; 33(10)2019 Oct 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31661149
19.
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
Lancet Oncol
; 19(5): e240-e251, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29726389
20.
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Prostate
; 78(8): 623-630, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29520847